BALTIMORE, June 22, 2011 /PRNewswire/ — Lupin
Pharmaceuticals, Inc. (LPI) announced today that the U.S. Food and
Drug Administration has granted final approval for the Company’s
Abbreviated New Drug Application (ANDA) to market a generic version
of Ortho McNeil’s Levaquin® (levofloxacin) tablets.
Commercial shipment of the product has commenced.
Lupin’s levofloxacin 250 mg, 500 mg and 750 mg tablets are the
AB-rated generic equivalent of Levaquin, a synthetic broad spectrum
antibacterial agent used to treat or prevent infections that are
proven or strongly suspected to be caused by susceptible bacteria.
Levaquin tablets had annual sales of approximately $1.6
billion for the twelve months ended March 2011, based on IMS Health
sales data.
About Lupin
Headquartered in Mumbai, India, Lupin Limited is an innovation
led transnational pharmaceutical company producing a wide range of
quality, affordable generic and branded formulations and APIs. The
Company today has significant market share in Cardiovascular (prils
and statins), Diabetology, Asthma, Pediatrics, CNS, GI,
Anti-Infectives and NSAIDs in addition holding global leadership
positions in the Anti-TB and Cephalosporins space.
Today, Lupin is the 5th largest and fastest growing Top 5
generics player in the US (by prescriptions), the only Asian
company to achieve that distinction. The company is also the
fastest growing top 10 pharmaceutical players in India, Japan and
South Africa. (IMS)
For the financial year ended March 2011, Lupin’s Consolidated
Revenues and Profit after Tax were Rs.57,068 million and Rs. 8,626
million respectively. Please visit http://www.lupinworld.com for
more information about Lupin Ltd.
Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary
of Lupin Limited. Headquartered in Baltimore, Maryland, Lupin
Pharmaceuticals, Inc. is dedicated to d
‘/>”/>
